{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:36Z","timestamp":1786118916211,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Neutrophil count is a risk factor for myocardial infarction (MI). Colchicine, a drug known as an anti-inflammatory, acts by selectively concentrating on neutrophils and impairing their function. Colchicine has been used successfully in the prevention of vascular events in patients with coronary artery disease (CAD), but recently the largest clinical trial carried out with colchicine in this clinical setting was unexpectedly neutral in the comparison of placebo and colchicine in patients with recent MI. Among the characteristics that distinguish patients with acute coronary syndromes (ACS) from established CAD is the dual antiplatelet therapy (DAPT), often consisting of aspirin and clopidogrel. Clopidogrel significantly reduces neutrophil count and could play a competitive role with colchicine by blunting its clinical effect.<\/jats:p>","DOI":"10.1097\/mca.0000000000001551","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:00:25Z","timestamp":1751608825000},"page":"630-632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Why colchicine is not beneficial in patients with acute coronary syndrome? In search of a CLEAR answer"],"prefix":"10.1097","volume":"36","author":[{"given":"Stefano","family":"De Servi","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Molteni","sequence":"additional","affiliation":[{"name":"Medical Department, Tradate Hospital, Azienda Ospedaliera di Varese, Azienda Socio Sanitaria dei Sette Laghi, Tradate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cimminiello","sequence":"additional","affiliation":[{"name":"Arianna Foundation on Anticoagulation, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"R1-20250925","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine \u2013 update on mechanisms of action and therapeutic uses.","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R2-20250925","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/cpt.3394","article-title":"The effect of low-dose colchicine on the phenotype and function of neutrophils and monocytes in patients with chronic coronary artery disease: a double-blind randomized placebo-controlled cross-over study.","volume":"116","author":"Tercan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R3-20250925","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"R4-20250925","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction.","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"R5-20250925","first-page":"843","article-title":"Efficacy and safety of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective.","volume":"13","author":"Tardif","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R6-20250925","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41569-025-01124-3","article-title":"Colchicine in acute coronary syndromes: the present and the possible future.","volume":"22","author":"Imazio","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"Suppl 1","key":"R7-20250925","article-title":"Cost and prescription trends of P2Y12 inhibitors in Australia over the last decade.","volume":"43","author":"Abrahams","year":"2022","journal-title":"Eur Heart J"},{"key":"R8-20250925","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2459\/JCM.0000000000001668","article-title":"Neutrophil count as a risk factor for cardiovascular diseases: how can we manage it?","volume":"25","author":"De Servi","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R9-20250925","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials.","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"key":"R10-20250925","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/MJT.0000000000001409","article-title":"Effect of colchicine in reducing inflammatory biomarkers and cardiovascular risk in coronary artery disease: a meta-analysis of clinical trials.","volume":"30","author":"Sethuramalingam","year":"2023","journal-title":"Am J Ther"},{"key":"R11-20250925","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome.","volume":"4","author":"Mart\u00ednez","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R12-20250925","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.3390\/ijms221910330","article-title":"Platelet inhibition prevents NLRP3 inflammasome activation and sepsis-induced kidney injury.","volume":"22","author":"Borges-Rodriguez","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R13-20250925","doi-asserted-by":"crossref","first-page":"e12808","DOI":"10.1002\/rth2.12808","article-title":"Building a better NET: neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders.","volume":"6","author":"Ngo","year":"2022","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:02:51Z","timestamp":1786035771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001551","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}